Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 35

Results For "EU"

4501 News Found

ABB India bags automation order for Reliance Life Sciences' biopharmaceutical facilities
Digitisation | August 21, 2023

ABB India bags automation order for Reliance Life Sciences' biopharmaceutical facilities

ABB India has secured an order from Reliance Life Sciences to deploy automation and control solutions for their new biosimilars and plasma proteins manufacturing facilities in Nashik, Maharashtra


Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%
Drug Approval | August 17, 2023

Glenmark Pharmaceuticals receives sANDA approval for Tacrolimus Ointment, 0.03%

Glenmark's current portfolio consists of 184 products authorized for distribution in the U.S. marketplace


Eugia Pharma receives USFDA Approval for Icatibant Injection
Drug Approval | August 16, 2023

Eugia Pharma receives USFDA Approval for Icatibant Injection

This is the 166th ANDA out of Eugia Pharma Speciality Group facilities


IOL Chemicals and Pharmaceuticals posts Q1 FY24 consolidated PAT at Rs. 45.86 Cr
News | August 10, 2023

IOL Chemicals and Pharmaceuticals posts Q1 FY24 consolidated PAT at Rs. 45.86 Cr

IOL Chemicals and Pharmaceuticals has reported total income of Rs. 570.24 crores during the period ended June 30, 2023


Torrent Pharmaceuticals posts Q1 FY 24 consolidated PAT at Rs. 378 Cr
News | August 08, 2023

Torrent Pharmaceuticals posts Q1 FY 24 consolidated PAT at Rs. 378 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2625 crores during the period ended June 30, 2023


Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP
Drug Approval | August 06, 2023

Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP

The product is being launched in August 2023


Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations
Drug Approval | August 05, 2023

Granules Pharmaceuticals successfully completes USFDA post marketing adverse drug experience inspection with zero observations

The inspection was conducted at Granules Pharmaceuticals Inc. (GPI) from July 31, 2023 to August 03, 2023


Jagsonpal Pharmaceuticals posts Q1 FY2024 PAT at Rs. 7.47 Cr
News | August 03, 2023

Jagsonpal Pharmaceuticals posts Q1 FY2024 PAT at Rs. 7.47 Cr

The company has reported total income of Rs. 62.15 crores during the period ended June 30, 2023


Fredun Pharmaceuticals achieves milestone in Pet Care Division
News | August 01, 2023

Fredun Pharmaceuticals achieves milestone in Pet Care Division

The company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision